Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
POTEN-C
Prostate Oncologic Therapy While Ensuring Neurovascular Conservation (POTEN-C)
- NCT03525262 ↗
- Active, not recruiting
- University of Texas Southwestern Medical Center
- Focused
We haven't built an HCP commentary report on POTEN-C (localized prostate cancer; tests no drug) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on POTEN-C so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 10 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Randomized Controlled Trial of Stereotactic Ablative Body Radiotherapy (SAbR) With or Without Neurovascular Sparing for Erectile Function Preservation in Localized Prostate Cancer
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Prostate Cancer Adenocarcinoma
- Interventions
- 30Gy (Gray) planning target volume (PTV)
- Arms
- SAbR WITHOUT Neurovascular sparing · No intervention
- SAbR WITH Neurovascular sparing · Experimental
- Enrollment
- 124
- Primary outcomes
- To compare the decline in patient health-related quality of life.
- Sponsor
- University of Texas Southwestern Medical Center with Boston Scientific Corporation
- Start
- Apr 24, 2018
- Primary completion
- Apr 2027 (estimated)
- Results posted
- No
- Registry record
- NCT03525262 · updated Jun 5, 2026